This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Halftime for Heidelberg
Spar, Debora L.Case HBS-720021-EStrategyThe case follows President Rob Huntington as he seeks to find a viable way forward for Heidelberg University. Located in Tiffin, Ohio, Heidelberg is a small, private, four-year university. As with many similar institutions of higher education, it currently faces a daunting and mounting set of challenges, most of which stem from financial and demographic changes that are far beyond its control. During Huntington's eleven-year tenure, the universi...Starting at €8.20
-
Afrigen Biologics: Vaccines for the Global South, Teaching Note
Spar, Debora L.; Comeau, JuliaTeaching Note HBS-323098-EEconomicsTeaching note to case 323030Starting at €0.00
-
The Social Purpose of the Firm
Spar, Debora L.; Comeau, JuliaCase HBS-323051-EKnowledge and CommunicationThe Social Purpose of the Firm (SPF) is a short module designed to explore how, and under what circumstances, business leaders can harness the power of capitalism and markets to "make a difference in the world" - that is, to address a significant societal problem as a commercial endeavor. This Module Note summarizes the cases and themes discussed in SPF. Together, the cases are designed to study entrepreneurs and business leaders who are tackling...Starting at €8.20
-
Extend Fertility: Conceiving the Market for Egg Preservation, Teaching Note
Spar, Debora L.; Hull, OliviaTeaching Note HBS-720002-EStrategyTeaching note for case 719019.Starting at €0.00
-
Afrigen Biologics: Vaccines for the Global South
Spar, Debora L.; Comeau, JuliaCase HBS-323030-EEconomicsThe majority of vaccines used on the continent of Africa (99%) are produced offshore. This makes African nations reliant on the West for major health care needs, a problem which was exacerbated by the COVID-19 pandemic. Afrigen Biologics (in partnership with the WHO) is seeking to lessen this disparity by putting vaccine production in the hands of South Africans and other low- and middle-income countries. Afrigen Biologics is the first in a plann...Starting at €8.20
-
Extend Fertility: Conceiving the Market for Egg Preservation (B)
Spar, Debora L.; Hull, OliviaCase HBS-720017-EStrategySupplement to case 719019Starting at €5.74
-
Afghanistan 2006: Building a Brand New State
Maurer, Noel; Spar, Debora L.; Trumbull, GunnarCase HBS-707033-EEconomicsIn 2006, Afghanistan remains a country in turmoil. It has a newly elected democratic government, a rebounding economy, and considerable economic potential. But the country is still torn by rival factions and dominated by the opium trade. Explores how Afghanistan has been rebuilt since the U.S. invasion of 2001, and what it means to create a modern state. Can state institutions be imposed from the outside? And what are the prospects for democracy ...Starting at €8.20
-
Halftime for Heidelberg, Teaching Note
Spar, Debora L.Teaching Note HBS-721385-EStrategyTeaching note for case 720021.Starting at €0.00
-
Extend Fertility: Conceiving the Market for Egg Preservation (A)
Spar, Debora L.; Hull, OliviaCase HBS-719019-EStrategyThe case follows entrepreneur Christy Jones as she tries to imagine, and then build, a firm that will enable young women to preserve their eggs -- and thus extend their fertility. In April 2003, entrepreneur and MBA student Christy Jones was planning a new venture to help women preserve their fertility. Her company, Extend Fertility, would commercialize a technique known as egg freezing, in which a woman's eggs were extracted and stored at low te...Starting at €8.20
-
Facebook Faces the Regulators
Spar, Debora L.Case HBS-720019-EEconomicsThe Inside the Case video that accompanies this case includes teaching tips and insight from the author (available to registered educators only). In the fall of 2019, Facebook and its CEO Mark Zuckerberg are facing increased scrutiny on multiple fronts. Regulators from around the globe are threatening the company with punitive measures. Users are organizing against it. But there is little consensus around what, precisely, Facebook has done wrong...Starting at €8.20